<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00939640</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00025253</org_study_id>
    <nct_id>NCT00939640</nct_id>
  </id_info>
  <brief_title>Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure</brief_title>
  <acronym>DASH-DHF</acronym>
  <official_title>Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet on Ventriculovascular Function in Heart Failure With Preserved Systolic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure with preserved systolic function (HF-PSF, or 'diastolic heart failure')
      accounts for half of hospitalizations for heart failure in patients over the age of 65. Most
      HF-PSF patients have systemic hypertension (HTN), and characteristic HTN-induced
      cardiovascular changes contribute to HF-PSF. However, it is unclear why most patients with
      HTN never develop HF-PSF or which specific aspects of HTN predispose to HF-PSF.

      In the Dahl S rat, the primary animal model of HF-PSF, high dietary sodium intake suppresses
      the systemic renin-angiotensin-aldosterone system, but upregulates renal and cardiac
      renin-angiotensin-aldosterone system by inducing oxidative stress. In humans, the magnitude
      of blood pressure response to sodium ingestion and depletion can categorize subjects as
      &quot;salt-resistant&quot; and &quot;salt-sensitive.&quot; Human salt sensitivity is associated with structural
      and loading conditions that increase the risk for HF-PSF, including HTN, ventricular
      hypertrophy and diastolic dysfunction, arterial stiffening, and increased plasma volume. High
      dietary sodium intake induces oxidative stress in salt-sensitive humans. In humans with HTN
      and normal ventricular systolic function that do not have heart failure, increased oxidative
      stress predicts impaired exercise capacity, ventricular hypertrophy, diastolic dysfunction,
      arterial stiffening, and vascular endothelial dysfunction. The investigators have proposed
      that &quot;salt sensitivity&quot; and the accompanying oxidative stress on the typical high-sodium
      Western diet may contribute to the initiation and progression of HF-PSF.

      In patients with HF-PSF, the investigators will relate dietary changes to biochemical and
      cardiovascular functional measures. The investigators will study subjects on ad-lib diet and
      and following three weeks of rigorous dietary modification with the Dietary Approaches to
      Stop Hypertension (DASH)/sodium-restricted diet (SRD). This diet is richer in natural
      antioxidants and lower in sodium than the usual American diet. The DASH/SRD is recommended to
      lower blood pressure in patients with HTN, and is particularly effective in elderly, obese,
      and salt-sensitive hypertensives. Dietary sodium restriction is recommended for all HF
      patients including those with HF-PSF. The investigators hypothesize that the DASH/SRD will
      have favorable effects on oxidative stress, ventricular and vascular function, and blood
      pressure control in patients with hypertensive HF-PSF.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brachial Artery Flow-mediated Dilation (FMD)</measure>
    <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean 24-hour Systolic Blood Pressure</measure>
    <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
    <description>Change in 24-hour systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diurnal Variation in Ambulatory Blood Pressure</measure>
    <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
    <description>Number of participants with non-dipping of nocturnal blood pressure - nighttime-to-daytime systolic BP ratio of &gt;= 0.9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic Augmentation Index</measure>
    <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
    <description>Aortic augmentation index is the ratio of the augmentation pressure to the central pulse pressure, expressed as a percentage. Both parameters are obtained via mathematical transformation of the radial pulse wave. The augmentation pressure represents the contribution of reflected waves to the pulse pressure. The central pulse pressure is the ratio between maximum aortic systolic pressure and minimum aortic diastolic pressure. A higher aortic augmentation index and central pulse pressure reflect increased arterial stiffness. Increased arterial stiffness is associated with an increased long-term risk of cardiovascular disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid-femoral Pulse Wave Velocity</measure>
    <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Diastolic Function</measure>
    <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
    <description>Lateral mitral annulus E/e' ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six Minute Walk Test Distance</measure>
    <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary 8-isoprostanes</measure>
    <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>EndoPAT Arterial Endothelial Function</measure>
    <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Estimated Glomerular Filtration Rate, Serum Potassium, Serum Calcium-phosphorus Product</measure>
    <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
    <description>Safety measures to determine adverse effects of the provided DASH diet home-delivered meals</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Diastolic Heart Failure</condition>
  <condition>Hypertensive Heart Disease</condition>
  <arm_group>
    <arm_group_label>Dietary intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>DASH/sodium-restricted diet (SRD)</intervention_name>
    <description>Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.</description>
    <arm_group_label>Dietary intervention</arm_group_label>
    <other_name>DASH diet</other_name>
    <other_name>sodium-restricted diet</other_name>
    <other_name>low sodium diet</other_name>
    <other_name>DASH-sodium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Satisfy European Society of Cardiology guidelines for the diagnosis of HF-PSF (Paulus
             WJ et al. Eur. Heart J. 2007;28:2539-2550).

          -  Framingham criteria for heart failure satisfied

          -  left ventricular ejection fraction ≥ 50% (contrast ventriculography, echocardiography,
             nuclear scintigraphy)

          -  Diastolic dysfunction on previous echocardiogram/catheterization or evidence of
             abnormal neurohormonal activation (B-type natriuretic peptide (BNP) ≥ 100 pg/ml) with
             supporting evidence (atrial fibrillation, left atrial enlargement, left ventricular
             hypertrophy)

          -  History of systemic hypertension

          -  Willing to adhere to provided diet

        Exclusion Criteria:

          -  New York Heart Association Class IV heart failure symptoms

          -  Hospitalization for decompensated heart failure within past one month

          -  Uncontrolled hypertension (seated systolic blood pressure ≥ 180 or diastolic blood
             pressure ≥ 110) at rest, on current antihypertensive regimen

          -  Changes in medical regimen for heart disease or hypertension within past 1 month,
             including diuretic dose adjustment

          -  Primary exercise limitation due to severe pulmonary disease

          -  Poor echocardiographic windows

          -  Worse than moderate mitral or aortic stenosis or insufficiency.

          -  Serum potassium level &gt; 5.0 mmol/L at baseline or prior history of serum potassium
             level &gt; 6.0

          -  Serum calcium/phosphorus product &gt; 50 at baseline

          -  Severe renal insufficiency (current estimated glomerular filtration rate &lt; 30 ml/min)

          -  Severe anemia (hemoglobin &lt; 9 g/dL)

          -  Uncontrolled diabetes mellitus (hemoglobin A1c &gt; 9%)

          -  Non-hypertensive cause of HF-PSF, e.g. amyloidosis, sarcoidosis, constrictive
             pericardial syndromes

          -  Myocardial infarction or unstable angina, including new or worsening anginal syndrome,
             within the past three months

          -  Uncontrolled arrhythmia (including non rate-controlled atrial fibrillation)

          -  Terminal illness expected to result in death within six months or active solid-organ
             cancer

          -  Psychiatric disorder or dementia with potential to compromise dietary adherence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott L Hummel, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/23033371</url>
    <description>Hypertension publication from this study</description>
  </link>
  <reference>
    <citation>Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006 Jul 20;355(3):251-9.</citation>
    <PMID>16855265</PMID>
  </reference>
  <reference>
    <citation>Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003 Jan 8;289(2):194-202.</citation>
    <PMID>12517230</PMID>
  </reference>
  <reference>
    <citation>Klotz S, Hay I, Zhang G, Maurer M, Wang J, Burkhoff D. Development of heart failure in chronic hypertensive Dahl rats: focus on heart failure with preserved ejection fraction. Hypertension. 2006 May;47(5):901-11. Epub 2006 Apr 3.</citation>
    <PMID>16585423</PMID>
  </reference>
  <reference>
    <citation>Laffer CL, Bolterman RJ, Romero JC, Elijovich F. Effect of salt on isoprostanes in salt-sensitive essential hypertension. Hypertension. 2006 Mar;47(3):434-40. Epub 2006 Jan 23.</citation>
    <PMID>16432053</PMID>
  </reference>
  <reference>
    <citation>Dekleva M, Celic V, Kostic N, Pencic B, Ivanovic AM, Caparevic Z. Left ventricular diastolic dysfunction is related to oxidative stress and exercise capacity in hypertensive patients with preserved systolic function. Cardiology. 2007;108(1):62-70. Epub 2006 Sep 25.</citation>
    <PMID>17003543</PMID>
  </reference>
  <reference>
    <citation>Yugar-Toledo JC, Bonalume Tácito LH, Ferreira-Melo SE, Sousa W, Consolin-Colombo F, Irigoyen MC, Franchini K, Coelho OR, Moreno H Jr. Low-renin (volume dependent) mild-hypertensive patients have impaired flow-mediated and glyceryl-trinitrate stimulated vascular reactivity. Circ J. 2005 Nov;69(11):1380-5.</citation>
    <PMID>16247215</PMID>
  </reference>
  <reference>
    <citation>Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001 Jan 4;344(1):3-10.</citation>
    <PMID>11136953</PMID>
  </reference>
  <reference>
    <citation>Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbély A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007 Oct;28(20):2539-50. Epub 2007 Apr 11.</citation>
    <PMID>17428822</PMID>
  </reference>
  <results_reference>
    <citation>Hummel SL, Seymour EM, Brook RD, Sheth SS, Ghosh E, Zhu S, Weder AB, Kovács SJ, Kolias TJ. Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction. Circ Heart Fail. 2013 Nov;6(6):1165-71. doi: 10.1161/CIRCHEARTFAILURE.113.000481. Epub 2013 Aug 28.</citation>
    <PMID>23985432</PMID>
  </results_reference>
  <results_reference>
    <citation>Hummel SL, Seymour EM, Brook RD, Kolias TJ, Sheth SS, Rosenblum HR, Wells JM, Weder AB. Low-sodium dietary approaches to stop hypertension diet reduces blood pressure, arterial stiffness, and oxidative stress in hypertensive heart failure with preserved ejection fraction. Hypertension. 2012 Nov;60(5):1200-6. doi: 10.1161/HYPERTENSIONAHA.112.202705. Epub 2012 Oct 1.</citation>
    <PMID>23033371</PMID>
  </results_reference>
  <results_reference>
    <citation>Mathew AV, Seymour EM, Byun J, Pennathur S, Hummel SL. Altered Metabolic Profile With Sodium-Restricted Dietary Approaches to Stop Hypertension Diet in Hypertensive Heart Failure With Preserved Ejection Fraction. J Card Fail. 2015 Dec;21(12):963-7. doi: 10.1016/j.cardfail.2015.10.003. Epub 2015 Oct 20.</citation>
    <PMID>26497755</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <results_first_submitted>July 16, 2013</results_first_submitted>
  <results_first_submitted_qc>February 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2018</results_first_posted>
  <last_update_submitted>October 13, 2019</last_update_submitted>
  <last_update_submitted_qc>October 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Scott L. Hummel</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Diet</keyword>
  <keyword>Sodium</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Potassium</keyword>
  <keyword>Antioxidants</keyword>
  <keyword>congestive heart failure</keyword>
  <keyword>Heart failure with normal ejection fraction</keyword>
  <keyword>Heart failure with preserved systolic function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>22 patients screened, 14 enrolled</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dietary Intervention</title>
          <description>Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.
DASH/sodium-restricted diet (SRD) : Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dietary Intervention</title>
          <description>Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.
DASH/sodium-restricted diet (SRD) : Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.5" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with Chronic Kidney Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary Artery Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants wtih Diabetes Mellitus</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants wtih Anemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Assocation Classification</title>
          <description>NYHA class:
I No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).
II Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea
III Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.
IV Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>NYHA Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with prior hospitalization due to heart failure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants on chronic loop diuretics</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants on 3 or more antihypertensive medications</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Brachial Artery Flow-mediated Dilation (FMD)</title>
        <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-dietary Intervention</title>
            <description>Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.
DASH/sodium-restricted diet (SRD) : Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.</description>
          </group>
          <group group_id="O2">
            <title>Post-dietary Intervention</title>
          </group>
        </group_list>
        <measure>
          <title>Brachial Artery Flow-mediated Dilation (FMD)</title>
          <units>% dilation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="5"/>
                    <measurement group_id="O2" value="8" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>.17</p_value>
            <method>Wilcoxon matched-pairs</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean 24-hour Systolic Blood Pressure</title>
        <description>Change in 24-hour systolic blood pressure</description>
        <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-dietary Intervention</title>
            <description>Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.
DASH/sodium-restricted diet (SRD) : Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.</description>
          </group>
          <group group_id="O2">
            <title>Post-dietary Intervention</title>
          </group>
        </group_list>
        <measure>
          <title>Mean 24-hour Systolic Blood Pressure</title>
          <description>Change in 24-hour systolic blood pressure</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" spread="4"/>
                    <measurement group_id="O2" value="123" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>.02</p_value>
            <method>Wilcoxon matched-pairs tests</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diurnal Variation in Ambulatory Blood Pressure</title>
        <description>Number of participants with non-dipping of nocturnal blood pressure - nighttime-to-daytime systolic BP ratio of &gt;= 0.9</description>
        <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-Dietary Intervention</title>
            <description>Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.
DASH/sodium-restricted diet (SRD): Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.</description>
          </group>
          <group group_id="O2">
            <title>Post-dietary Intervention</title>
            <description>Post-dietary intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Diurnal Variation in Ambulatory Blood Pressure</title>
          <description>Number of participants with non-dipping of nocturnal blood pressure - nighttime-to-daytime systolic BP ratio of &gt;= 0.9</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aortic Augmentation Index</title>
        <description>Aortic augmentation index is the ratio of the augmentation pressure to the central pulse pressure, expressed as a percentage. Both parameters are obtained via mathematical transformation of the radial pulse wave. The augmentation pressure represents the contribution of reflected waves to the pulse pressure. The central pulse pressure is the ratio between maximum aortic systolic pressure and minimum aortic diastolic pressure. A higher aortic augmentation index and central pulse pressure reflect increased arterial stiffness. Increased arterial stiffness is associated with an increased long-term risk of cardiovascular disease.</description>
        <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-Dietary Intervention</title>
            <description>Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.
DASH/sodium-restricted diet (SRD): Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.</description>
          </group>
          <group group_id="O2">
            <title>Post-dietary Intervention</title>
          </group>
        </group_list>
        <measure>
          <title>Aortic Augmentation Index</title>
          <description>Aortic augmentation index is the ratio of the augmentation pressure to the central pulse pressure, expressed as a percentage. Both parameters are obtained via mathematical transformation of the radial pulse wave. The augmentation pressure represents the contribution of reflected waves to the pulse pressure. The central pulse pressure is the ratio between maximum aortic systolic pressure and minimum aortic diastolic pressure. A higher aortic augmentation index and central pulse pressure reflect increased arterial stiffness. Increased arterial stiffness is associated with an increased long-term risk of cardiovascular disease.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" spread="9"/>
                    <measurement group_id="O2" value="28" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carotid-femoral Pulse Wave Velocity</title>
        <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-Dietary Intervention</title>
            <description>Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.
DASH/sodium-restricted diet (SRD): Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.</description>
          </group>
          <group group_id="O2">
            <title>Post-Dietary Intervention</title>
          </group>
        </group_list>
        <measure>
          <title>Carotid-femoral Pulse Wave Velocity</title>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="3"/>
                    <measurement group_id="O2" value="11.0" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventricular Diastolic Function</title>
        <description>Lateral mitral annulus E/e' ratio</description>
        <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-Dietary Intervention</title>
            <description>Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.
DASH/sodium-restricted diet (SRD): Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.</description>
          </group>
          <group group_id="O2">
            <title>Post-Dietary Intervention</title>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Diastolic Function</title>
          <description>Lateral mitral annulus E/e' ratio</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="2"/>
                    <measurement group_id="O2" value="11" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Six Minute Walk Test Distance</title>
        <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-Dietary Intervention</title>
            <description>Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.
DASH/sodium-restricted diet (SRD) : Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.</description>
          </group>
          <group group_id="O2">
            <title>Post-Dietary Intervention</title>
          </group>
        </group_list>
        <measure>
          <title>Six Minute Walk Test Distance</title>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="313" spread="86"/>
                    <measurement group_id="O2" value="337" spread="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.006</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary 8-isoprostanes</title>
        <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-Dietary Intervention</title>
            <description>Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.
DASH/sodium-restricted diet (SRD): Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.</description>
          </group>
          <group group_id="O2">
            <title>Post-Dietary Intervention</title>
          </group>
        </group_list>
        <measure>
          <title>Urinary 8-isoprostanes</title>
          <units>mmol F2-iso/mmol Cr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" spread="28"/>
                    <measurement group_id="O2" value="48" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.02</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>EndoPAT Arterial Endothelial Function</title>
        <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Estimated Glomerular Filtration Rate, Serum Potassium, Serum Calcium-phosphorus Product</title>
        <description>Safety measures to determine adverse effects of the provided DASH diet home-delivered meals</description>
        <time_frame>Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>25 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dietary Intervention</title>
          <description>Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.
DASH/sodium-restricted diet (SRD) : Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <description>At day 5 safety visit 1 subject had serum potassium 5.9, an expected potential adverse event in this protocol. There were no associated symptoms or sequelae, and the patient was withdrawn form the study diet as per protocol.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Scott Hummel</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734-998-7991</phone>
      <email>scothumm@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

